Johnson & Johnson MedTech’s Biosense Webster division presented new clinical data backing up its pulsed field ablation ...

In the pivotal phase of the admIRE trial, the VARIPULSE™ Platform demonstrated 85% peak primary effectiveness with minimal adverse events, short PFA application times, and low fluoroscopy exposure ...

Johnson & Johnson MedTech’s Biosense Webster shared results from a clinical trial of its Varipulse pulsed field ablation (PFA ...

Johnson & Johnson MedTech division Biosense Webster has secured European CE mark approval for its Varipulse pulsed field ...

Once again, the top players in cardiac care gathered en masse as Heart Rhythm Society (HRS) 2024 took place in Boston last ...

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO™ 3 System Version 8, the latest version of the company's ...

No differences were seen between groups in any safety endpoints. Deisenhofer disclosed relationships with Abbott Medical, ...

BOSTON -- An olive oil-enhanced Mediterranean diet didn't help prevent atrial fibrillation (Afib, or AF) recurrence after ...

Irvine: Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, has ...

IRVINE, Calif., May 8, 2024 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the launch of CARTO ™ 3 ...